乙胺碘呋酮在心肌病并心功能不全患者中的应用

Clinical application efficacy and safety of amiodarone in patients with cardiomyopathy combined with cardiac functional insufficiency

目的重点研究和探讨乙胺碘呋酮治疗心肌病并心功能不全的患者的临床疗效及安全性。方法回顾性分析我院2009年1月～2012年12月收治的72例心肌病心功能不全并存在不同类型心律失常的患者的临床资料。将运用对比分析的方法,比较乙胺碘呋酮治疗心肌病并心功能不全患者在治疗前和治疗后的情况,对患者治疗前后的心功能、室性期前收缩、心率、心动过速的情况进行比较和探讨。结果乙胺碘呋酮治疗心肌病并心功能不全患者的相比较治疗前,室性期前收缩、心率、心动过速等均有有明显的下降和好转,心功能无不利影响,并因心率减慢或心律失常控制有一定改善。结论乙胺碘呋酮治疗心肌病心功能不全并存在心律失常的患者具有较好的临床疗效,并且具有良好的安全性,目前已经成为治疗心肌病心功能不全存在较高猝死风险的患者的主要方法,对我国治疗心肌病并心功能不全的患者的发展具有重要价值。

Objective To study and explore mainly the clinical application efficacy and safety of amiodarone in patients with cardiomyopathy combined with cardiac functional insufficiency. Methods The clinical dates of 72 cases with cardiomyopathy combined with cardiac functional insufficiency and different types of arrhythmia in our hospital from January 2009 to December 2012 were retrospectively analyzed and compared. The cardiac function, premature ventricualr contraction, heart rate and tachycardia of patients before and after treatment were compared and explored. Results Compared with before treatment, the premature ventricualr contraction, heart rate and tachycardia of patients with cardiomyopathy combined with cardiac functional insufficiency declined and improved more significantly after treatment,the cardiac function had not bad effect and some improvement due to heart rate slow down and arrhythmia control. Conclusion It has good clinical efficacy and safety that amiodarone cure cardiomyopathy combined with cardiac functional insufficiency and arrhythmia. Amiodarone is the major treatment method for the patients with cardiomyopathy combined with cardiac functional insufficiency having a higher sudden death risk, and has important value for the treatment development of the patients with cardiomyopathy combined with cardiac functional insufficiency in China.